Novartis expands Phase II and III trials in India
NewsBytes | May 11, 2026 7:40 PM CST
Novartis keeps unlisted India arm
In February, Novartis sold most of its listed Indian unit but kept its unlisted arm focused on cutting-edge medicines.
With over 9,000 employees here and development hubs in Hyderabad and Mumbai (alongside Basel and the U.S.), India has helped deliver important treatments like Coartem Baby and Inclisiran.
Novartis says it's committed to bringing even more new therapies from India to the world.
READ NEXT
-
STI nearly eradicated has surged and it’s raising heart attack risk
-
IPL 2026: GT defeated SRH by 82 runs, achieved fifth consecutive win, became table topper
-
‘You were my only friend…’, an elderly woman cried bitterly over the death of her pet cat.
-
Health Tips- Find out whether there is enough iron in the body or not
-
Google Translate completes 20 years, most translated in the world Thank You
